|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
2.
|
Videtic GM: Locally advanced non-small
cell lung cancer: what is the optimal concurrent chemoradiation
regimen? Cleve Clin J Med. 79(Electronic Suppl 1): eS32–eS37. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ishikura S: Optimal radiotherapy for
non-small-cell lung cancer: current progress and future challenges.
Gen Thorac Cardiovasc Surg. 60:127–131. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bretthauer M: Evidence for colorectal
cancer screening. Best Pract Res Clin Gastroenterol. 24:417–425.
2010. View Article : Google Scholar
|
|
5.
|
Niccolai E and Amedei A: Vaccine
immunotherapy strategies in colorectal cancer treatment. Single
Cell Biol. 1:e10001022012.
|
|
6.
|
Yaddanapudi K, Mitchell RA, Putty K,
Willer S, Sharma RK, Yan J, Bodduluri H and Eaton JW: Vaccination
with embryonic stem cells protects against lung cancer: is a
broad-spectrum prophylactic vaccine against cancer possible? PLoS
One. 7:e422892012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Armstrong AC and Gilham DE: Targeting
breast cancer vaccines to dendritic cells: improved immunological
responses with less protein? Breast Cancer Res.
14:1062012.PubMed/NCBI
|
|
8.
|
Kalinski P and Okada H: Polarized
dendritic cells as cancer vaccines: directing effector-type T cells
to tumors. Semin Immunol. 22:173–182. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Steinman RM: Decisions about dendritic
cells: past, present, and future. Annu Rev Immunol. 30:1–22. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Barth RJ Jr, Fisher DA, Wallace PK,
Channon JY, Noelle RJ, Gui J and Ernstoff MS: A randomized trial of
ex vivo CD40L activation of a dendritic cell vaccine in colorectal
cancer patients: tumor-specific immune responses are associated
with improved survival. Clin Cancer Res. 16:5548–5556. 2010.
View Article : Google Scholar
|
|
11.
|
Lesterhuis WJ, de Vries IJ, Schreibelt G,
Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW,
de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman
OC, Lucas S, Adema GJ, Punt CJ and Figdor CG: Route of
administration modulates the induction of dendritic cell
vaccine-induced antigen-specific T cells in advanced melanoma
patients. Clin Cancer Res. 17:5725–5735. 2011. View Article : Google Scholar
|
|
12.
|
Gilboa E: DC-based cancer vaccines. J Clin
Invest. 117:1195–1203. 2007. View
Article : Google Scholar
|
|
13.
|
Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu
XF and Wang HX: Cytokine-induced killer cells in the treatment of
patients with solid carcinomas: a systematic review and pooled
analysis. Cytotherapy. 14:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Joshi PS, Liu JQ, Wang Y, Chang X,
Richards J, Assarsson E, Shi FD, Ljunggren HG and Bai XF:
Cytokine-induced killer T cells kill immature dendritic cells by
TCR-independent and perforin-dependent mechanisms. J Leukoc Biol.
80:1345–1353. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Zhang S, Wang Q, Li WF, Wang HY, Zhang HJ
and Zhu JJ: Different antitumor immunity roles of cytokine
activated T lymphocytes from naive murine splenocytes and from
dendritic cells-based vaccine primed splenocytes: implications for
adoptive immunotherapy. Eksp Onkol. 26:55–62. 2004.
|
|
16.
|
Nagaraj S, Ziske C and Schmidt-Wolf IG:
Human cytokine-induced killer cells have enhanced in vitro
cytolytic activity via non-viral interleukin-2 gene transfer. Genet
Vaccines Ther. 2:122004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Frank MO, Kaufman J, Tian S,
Suárez-Fariñas M, Parveen S, Blachère NE, Morris MJ, Slovin S,
Scher HI, Albert ML and Darnell RB: Harnessing naturally occurring
tumor immunity: a clinical vaccine trial in prostate cancer. PLoS
One. 5:e123672010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Nicol AJ, Tazbirkova A and Nieda M:
Comparison of clinical and immunological effects of intravenous and
intradermal administration of α-galactosylceramide (KRN7000)-pulsed
dendritic cells. Clin Cancer Res. 17:5140–5151. 2011.PubMed/NCBI
|
|
19.
|
Zhang SN, Choi IK, Huang JH, Yoo JY, Choi
KJ and Yun CO: Optimizing DC vaccination by combination with
oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther.
19:1558–1568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu
XF and Wang HX: Cytokine-induced killer cells in the treatment of
patients with solid carcinomas: a systematic review and pooled
analysis. Cytotherapy. 14:483–493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Chang XH, Cheng HY, Cheng YX, Ye X, Guo
HF, Fu TY, Zhang L, Zhang G and Cui H: Specific immune cell therapy
against ovarian cancer in vivo and in vitro. Ai Zheng.
27:1244–1250. 2008.(In Chinese).
|
|
22.
|
Kim BR, Yang EK, Kim DY, Kim SH, Moon DC,
Lee JH, Kim HJ and Lee JC: Generation of anti-tumour immune
response using dendritic cells pulsed with carbonic anhydrase
IX-Acinetobacter baumannii outer membrane protein A fusion
proteins against renal cell carcinoma. Clin Exp Immunol. 167:73–83.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Schwaab T, Schwarzer A, Wolf B, Crocenzi
TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC,
Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR,
Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ and Ernstoff MS:
Clinical and immunologic effects of intranodal autologous tumor
lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and
IFN-(alpha)2a therapy in metastatic renal cell carcinoma patients.
Clin Cancer Res. 15:4986–4992. 2009. View Article : Google Scholar
|
|
24.
|
Jähnisch H, Füssel S, Kiessling A, Wehner
R, Zastrow S, Bachmann M, Rieber EP, Wirth MP and Schmitz M:
Dendritic cell-based immunotherapy for prostate cancer. Clin Dev
Immunol. 2010:5174932010.PubMed/NCBI
|
|
25.
|
Liu Y, Zhang W, Zhang B, Yin X and Pang Y:
DC Vaccine therapy combined concurrently with oral capecitabine in
meta-static colorectal cancer patients. Hepatogastroenterology.
60:hge125222012.PubMed/NCBI
|
|
26.
|
Kalos M: Biomarkers in T cell therapy
clinical trials. J Transl Med. 9:1382011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Soliman H: Developing an effective breast
cancer vaccine. Cancer Control. 17:183–190. 2010.PubMed/NCBI
|
|
28.
|
Hoos A, Eggermont AM, Janetzki S, Hodi FS,
Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L and Wolchok
J: Improved endpoints for cancer immunotherapy trials. J Natl
Cancer Inst. 102:1388–1397. 2010. View Article : Google Scholar : PubMed/NCBI
|
